Literature DB >> 22787196

IgG antibody response to toxins A and B in patients with Clostridium difficile infection.

M Wullt1, T Norén, A Ljungh, T Åkerlund.   

Abstract

IgG antibodies against Clostridium difficile toxins A and B were followed in controls and in patients with an initial C. difficile infection (CDI). Of the 50 CDI patients, 38 were cured and 12 developed recurrence. Compared to controls, patients had significantly lower anti-toxin A and B IgGs at inclusion, but the subsequent levels rose slightly regardless of clinical outcome. The results imply that the general serum reactivity against toxins A and B in the population reduces the risk of CDI, which suggests implications for vaccine strategies.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22787196      PMCID： PMC3428380          DOI： 10.1128/CVI.00210-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  13 in total

1.  Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection.

Authors:  Mary Y Hu; Kianoosh Katchar; Lorraine Kyne; Seema Maroo; Sanjeev Tummala; Valley Dreisbach; Hua Xu; Daniel A Leffler; Ciarán P Kelly
Journal:  Gastroenterology       Date:  2008-12-13       Impact factor: 22.682

2.  Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

Authors:  L Kyne; M Warny; A Qamar; C P Kelly
Journal:  N Engl J Med       Date:  2000-02-10       Impact factor: 91.245

3.  Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea.

Authors:  L Kyne; M Warny; A Qamar; C P Kelly
Journal:  Lancet       Date:  2001-01-20       Impact factor: 79.321

4.  Treatment with monoclonal antibodies against Clostridium difficile toxins.

Authors:  Israel Lowy; Deborah C Molrine; Brett A Leav; Barbra M Blair; Roger Baxter; Dale N Gerding; Geoffrey Nichol; William D Thomas; Mark Leney; Susan Sloan; Catherine A Hay; Donna M Ambrosino
Journal:  N Engl J Med       Date:  2010-01-21       Impact factor: 91.245

5.  Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection.

Authors:  M Warny; J P Vaerman; V Avesani; M Delmée
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

6.  Serum antibody response to toxins A and B of Clostridium difficile.

Authors:  R Viscidi; B E Laughon; R Yolken; P Bo-Linn; T Moench; R W Ryder; J G Bartlett
Journal:  J Infect Dis       Date:  1983-07       Impact factor: 5.226

7.  Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile.

Authors:  S Johnson; D N Gerding; E N Janoff
Journal:  J Infect Dis       Date:  1992-12       Impact factor: 5.226

8.  A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea.

Authors:  Marlene Wullt; Inga Odenholt
Journal:  J Antimicrob Chemother       Date:  2004-05-26       Impact factor: 5.790

9.  Characterisation and carriage ratio of Clostridium difficile strains isolated from a community-dwelling elderly population in the United Kingdom.

Authors:  Fabio Miyajima; Paul Roberts; Andrew Swale; Valerie Price; Maureen Jones; Michael Horan; Nicholas Beeching; Jonathan Brazier; Christopher Parry; Neil Pendleton; Munir Pirmohamed
Journal:  PLoS One       Date:  2011-08-23       Impact factor: 3.240

10.  Toxin B is essential for virulence of Clostridium difficile.

Authors:  Dena Lyras; Jennifer R O'Connor; Pauline M Howarth; Susan P Sambol; Glen P Carter; Tongted Phumoonna; Rachael Poon; Vicki Adams; Gayatri Vedantam; Stuart Johnson; Dale N Gerding; Julian I Rood
Journal:  Nature       Date:  2009-03-01       Impact factor: 49.962
View more
  14 in total

Review 1.  Antibodies for treatment of Clostridium difficile infection.

Authors:  David P Humphreys; Mark H Wilcox
Journal:  Clin Vaccine Immunol       Date:  2014-04-30

Review 2.  [Clostridium difficile infections in geriatric patients].

Authors:  R Simmerlein; A Basta; M Gosch
Journal:  Z Gerontol Geriatr       Date:  2016-10-26       Impact factor: 1.281

3.  Host Immune Response to Clostridium difficile Infection in Inflammatory Bowel Disease Patients.

Authors:  Michelle Hughes; Taha Qazi; Adam Berg; Janice Weinberg; Xinhua Chen; Ciaran P Kelly; Francis A Farraye
Journal:  Inflamm Bowel Dis       Date:  2016-04       Impact factor: 5.325

Review 4.  Structural and functional changes within the gut microbiota and susceptibility to Clostridium difficile infection.

Authors:  Caná L Ross; Jennifer K Spinler; Tor C Savidge
Journal:  Anaerobe       Date:  2016-05-12       Impact factor: 3.331

5.  Biochemical and Immunological Characterization of Truncated Fragments of the Receptor-Binding Domains of C. difficile Toxin A.

Authors:  Jui-Hsin Huang; Zhe-Qing Shen; Shu-Pei Lien; Kuang-Nan Hsiao; Chih-Hsiang Leng; Chi-Chang Chen; Leung-Kei Siu; Pele Choi-Sing Chong
Journal:  PLoS One       Date:  2015-08-13       Impact factor: 3.240

Review 6.  Collateral damage during antibiotic treatment of C. difficile infection in the aged host: Insights into why recurrent disease happens.

Authors:  Jae Hyun Shin; Cirle A Warren
Journal:  Gut Microbes       Date:  2017-04-28

7.  Anti-toxin antibody is not associated with recurrent Clostridium difficile infection.

Authors:  Julie Gilbert; Jhansi Leslie; Rose Putler; Shayna Weiner; Alexandra Standke; Aline Penkevich; Micah Keidan; Vincent B Young; Krishna Rao
Journal:  Anaerobe       Date:  2020-11-21       Impact factor: 3.331

Review 8.  Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.

Authors:  Lissa S Tsutsumi; Yaw B Owusu; Julian G Hurdle; Dianqing Sun
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

9.  High prevalence of subclass-specific binding and neutralizing antibodies against Clostridium difficile toxins in adult cystic fibrosis sera: possible mode of immunoprotection against symptomatic C. difficile infection.

Authors:  Tanya M Monaghan; Ola H Negm; Brendon MacKenzie; Mohamed R Hamed; Clifford C Shone; David P Humphreys; K Ravi Acharya; Mark H Wilcox
Journal:  Clin Exp Gastroenterol       Date:  2017-07-19

10.  Humoral Immune Response to Clostridioides difficile Toxins A and B in Hospitalized Immunocompromised Patients With C difficile Infection.

Authors:  Carolyn D Alonso; Konstantinos Papamichael; Rebecca Sprague; Caitlin Barrett; Anne J Gonzales-Luna; Kaitlyn Daugherty; Kevin W Garey; Javier Villafuerte-Gálvez; Hua Xu; Qianyun Lin; Lamei Wang; Xinhua Chen; Nira R Pollock; Ciarán P Kelly
Journal:  Open Forum Infect Dis       Date:  2021-06-01       Impact factor: 3.835
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.